vs

Side-by-side financial comparison of IMMUCELL CORP (ICCC) and SES AI Corp (SES). Click either name above to swap in a different company.

IMMUCELL CORP is the larger business by last-quarter revenue ($5.5M vs $4.6M, roughly 1.2× SES AI Corp). IMMUCELL CORP runs the higher net margin — -2.5% vs -373.5%, a 370.9% gap on every dollar of revenue. IMMUCELL CORP produced more free cash flow last quarter ($-1.8M vs $-11.1M).

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

SES S.A. is a Luxembourgish communications satellite operator supplying video and data connectivity worldwide to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions.

ICCC vs SES — Head-to-Head

Bigger by revenue
ICCC
ICCC
1.2× larger
ICCC
$5.5M
$4.6M
SES
Higher net margin
ICCC
ICCC
370.9% more per $
ICCC
-2.5%
-373.5%
SES
More free cash flow
ICCC
ICCC
$9.3M more FCF
ICCC
$-1.8M
$-11.1M
SES

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ICCC
ICCC
SES
SES
Revenue
$5.5M
$4.6M
Net Profit
$-139.7K
$-17.0M
Gross Margin
42.9%
11.3%
Operating Margin
0.4%
-387.7%
Net Margin
-2.5%
-373.5%
Revenue YoY
-8.4%
Net Profit YoY
80.1%
50.7%
EPS (diluted)
$-0.02
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICCC
ICCC
SES
SES
Q4 25
$4.6M
Q3 25
$5.5M
$7.1M
Q2 25
$6.4M
$3.5M
Q1 25
$8.1M
$5.8M
Q4 24
$7.8M
Q3 24
$6.0M
Q2 24
$5.5M
Q1 24
$7.3M
Net Profit
ICCC
ICCC
SES
SES
Q4 25
$-17.0M
Q3 25
$-139.7K
$-20.9M
Q2 25
$501.9K
$-22.7M
Q1 25
$1.4M
$-12.4M
Q4 24
Q3 24
$-701.7K
Q2 24
$-1.5M
Q1 24
$-437.9K
Gross Margin
ICCC
ICCC
SES
SES
Q4 25
11.3%
Q3 25
42.9%
51.1%
Q2 25
43.7%
73.7%
Q1 25
41.6%
78.7%
Q4 24
36.5%
Q3 24
26.3%
Q2 24
22.5%
Q1 24
31.6%
Operating Margin
ICCC
ICCC
SES
SES
Q4 25
-387.7%
Q3 25
0.4%
-262.0%
Q2 25
8.8%
-652.3%
Q1 25
13.9%
-401.7%
Q4 24
8.0%
Q3 24
-9.6%
Q2 24
-25.3%
Q1 24
-4.1%
Net Margin
ICCC
ICCC
SES
SES
Q4 25
-373.5%
Q3 25
-2.5%
-293.9%
Q2 25
7.8%
-642.2%
Q1 25
17.9%
-214.6%
Q4 24
Q3 24
-11.7%
Q2 24
-28.0%
Q1 24
-6.0%
EPS (diluted)
ICCC
ICCC
SES
SES
Q4 25
$-0.05
Q3 25
$-0.02
$-0.06
Q2 25
$0.06
$-0.07
Q1 25
$0.16
$-0.04
Q4 24
$0.09
Q3 24
$-0.09
Q2 24
$-0.20
Q1 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICCC
ICCC
SES
SES
Cash + ST InvestmentsLiquidity on hand
$3.9M
$29.5M
Total DebtLower is stronger
$9.5M
Stockholders' EquityBook value
$29.8M
$214.8M
Total Assets
$45.7M
$272.6M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICCC
ICCC
SES
SES
Q4 25
$29.5M
Q3 25
$3.9M
$35.3M
Q2 25
$11.8M
Q1 25
$56.1M
Q4 24
$3.8M
Q3 24
Q2 24
$1.3M
Q1 24
$960.3K
Total Debt
ICCC
ICCC
SES
SES
Q4 25
Q3 25
$9.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
ICCC
ICCC
SES
SES
Q4 25
$214.8M
Q3 25
$29.8M
$228.2M
Q2 25
$29.9M
$249.2M
Q1 25
$29.0M
$269.9M
Q4 24
$27.5M
Q3 24
$26.4M
Q2 24
$23.5M
Q1 24
$24.6M
Total Assets
ICCC
ICCC
SES
SES
Q4 25
$272.6M
Q3 25
$45.7M
$288.8M
Q2 25
$46.7M
$290.5M
Q1 25
$45.6M
$306.0M
Q4 24
$45.1M
Q3 24
$44.4M
Q2 24
$41.9M
Q1 24
$43.1M
Debt / Equity
ICCC
ICCC
SES
SES
Q4 25
Q3 25
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICCC
ICCC
SES
SES
Operating Cash FlowLast quarter
$-1.2M
$-10.4M
Free Cash FlowOCF − Capex
$-1.8M
$-11.1M
FCF MarginFCF / Revenue
-32.3%
-243.7%
Capex IntensityCapex / Revenue
10.8%
15.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$715.4K
$-61.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICCC
ICCC
SES
SES
Q4 25
$-10.4M
Q3 25
$-1.2M
$-14.3M
Q2 25
$1.6M
$-10.8M
Q1 25
$1.6M
$-22.8M
Q4 24
$-3.1K
Q3 24
$-639.3K
Q2 24
$581.8K
Q1 24
$418.5K
Free Cash Flow
ICCC
ICCC
SES
SES
Q4 25
$-11.1M
Q3 25
$-1.8M
$-14.7M
Q2 25
$1.4M
$-11.6M
Q1 25
$1.2M
$-23.7M
Q4 24
$-199.3K
Q3 24
$-727.7K
Q2 24
$471.0K
Q1 24
$348.1K
FCF Margin
ICCC
ICCC
SES
SES
Q4 25
-243.7%
Q3 25
-32.3%
-206.9%
Q2 25
22.4%
-329.6%
Q1 25
15.4%
-410.0%
Q4 24
-2.6%
Q3 24
-12.1%
Q2 24
8.6%
Q1 24
4.8%
Capex Intensity
ICCC
ICCC
SES
SES
Q4 25
15.6%
Q3 25
10.8%
6.0%
Q2 25
2.4%
22.8%
Q1 25
4.1%
15.8%
Q4 24
2.5%
Q3 24
1.5%
Q2 24
2.0%
Q1 24
1.0%
Cash Conversion
ICCC
ICCC
SES
SES
Q4 25
Q3 25
Q2 25
3.19×
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons